Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C243 is a potent and selective small molecule inhibitor of the NLRP3 (NOD-like receptor protein 3) inflammasome. The NLRP3 inflammasome is a multi-protein complex that plays a critical role in the innate immune system by mediating the release of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18), in response to various danger signals. C243 specifically targets the NLRP3 protein, preventing its activation and the subsequent assembly of the inflammasome complex. This inhibition effectively blocks the maturation and secretion of IL-1β, thereby reducing systemic and local inflammation. C243 is primarily utilized in preclinical research to investigate the role of NLRP3 in various inflammatory and autoimmune conditions, including gout, type 2 diabetes, and neurodegenerative diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C243.